Related Experiment Videos
[Microcellular bronchial cancer. Current general and therapeutic problems]
Abstract:
Small cell carcinomas constitute about 15-20% of all primary lung tumours. They are divided into oat cell and intermediate cell carcinomas. Pathognomonic neurosecretory granules have been detected in the cytoplasm of these cells by electron microscopy. Their ectodermic origin is now questioned by some authors. The treatment and prognosis of these carcinomas vary according to whether they are initially localized or diffuse. Chemotherapy in biphasic courses seems to be required to obtain complete remission. Mediastinal radiotherapy may help control the initial lesion. Surgery is no longer to be avoided in all cases. Small cell carcinomas are usually lethal, but their median survival time has increased over the last few years.
Insights
Small cell lung cancer (SCLC) is a significant portion of lung tumors. While typically lethal, advancements in chemotherapy and radiotherapy are improving median survival times.
Area of Science:
- Oncology
- Pulmonology
- Cell Biology
Context:
- Small cell carcinomas represent 15-20% of primary lung tumors.
- These tumors exhibit pathognomonic neurosecretory granules.
- The cellular origin of small cell carcinomas is under investigation.
Purpose:
- To review the classification, diagnosis, and treatment of small cell lung carcinomas.
- To discuss the evolving understanding of small cell lung carcinoma origins.
- To outline current therapeutic strategies and their impact on prognosis.
Summary:
- Small cell carcinomas are classified into oat cell and intermediate cell types, identified by neurosecretory granules.
- Treatment involves biphasic chemotherapy for remission and mediastinal radiotherapy for local control.
- Surgery is increasingly considered in the management of localized disease.
Impact:
- Improved median survival times for small cell lung cancer patients.
- Enhanced understanding of tumor biology influencing treatment strategies.
- Multimodal therapeutic approaches are key to managing this aggressive cancer.